AustralianSuper Pty Ltd Purchases Shares of 1,323 argenex SE $ARGX

AustralianSuper Pty Ltd purchased a new stake in argenex SE (NASDAQ:ARGX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,323 shares of the company’s stock, valued at approximately $1,113,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capital World Investors lifted its position in shares of argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after purchasing an additional 8,422 shares during the last quarter. M&T Bank Corp lifted its position in shares of argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares during the last quarter. Bank of America Corp DE lifted its position in shares of argenex by 1.9% during the 3rd quarter. Bank of America Corp DE now owns 342,379 shares of the company’s stock worth $252,525,000 after purchasing an additional 6,259 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $799.32 on Friday. The company’s fifty day moving average price is $760.29 and its 200 day moving average price is $816.75. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The firm has a market capitalization of $49.71 billion, a P/E ratio of 35.59, a P/E/G ratio of 1.31 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The firm had revenue of $1.31 billion for the quarter. On average, sell-side analysts anticipate that argenex SE will post 25.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Guggenheim lifted their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, HC Wainwright lifted their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.